Why FMC’s latest earnings and guidance matter for shareholders

FMC (FMC) recently reported a fourth quarter and full year 2025 loss and paired those results with 2026 revenue guidance that points to a 5% decline at the midpoint for both the first quarter and full year.

Management cited delayed customer collections in Brazil, the sale of its India business, and increased generic competition as ongoing headwinds. The company also filed a shelf registration for an employee stock plan, which adds another consideration for investors tracking potential share issuance.

Despite the weak 2025 results and softer 2026 guidance, FMC’s recent share price momentum has been strong, with a 30 day share price return of 20.58% and a 90 day share price return of 30.99%. However, the 1 year total shareholder return is a 50.24% loss, suggesting short term sentiment has improved after a difficult stretch for longer term holders.

If this earnings reset has you reassessing your watchlist, it could be a useful moment to broaden your search and check out fast growing stocks with high insider ownership.

With FMC shares still 50% below their 1 year total return level but recently rallying and trading at a discount to the average analyst price target and an estimated intrinsic value, is this a reset that creates an opportunity, or a sign that markets are already pricing in whatever comes next?

Most Popular Narrative: 31.8% Undervalued

FMC’s most followed narrative pegs fair value at about $24.92 using a 12.5% discount rate, compared with the latest close of $16.99, which implies a material gap the market has not closed.

Ongoing cost transformation, including lower manufacturing costs for key products like Rynaxypyr and benefits from 2024 to 2025 restructuring, creates durable COGS reductions and improved fixed cost absorption, serving as a catalyst for sustainable EBITDA and net margin improvement.

Want to see what kind of revenue path and margin rebuild has to line up for that fair value to hold? The narrative leans on a detailed earnings ramp and a future profit multiple that assumes sentiment eventually normalizes. Curious which specific cash flow assumptions are doing the heavy lifting in that $24.92 figure?

Result: Fair Value of $24.92 (UNDERVALUED)

However, you also have to weigh tighter regulatory scrutiny and ongoing generic competition, as either could pressure margins and undercut that repaired cash flow story.

Build Your Own FMC Narrative

If you look at the numbers and reach a different conclusion, or just prefer to build your own view from scratch, you can sketch out a custom FMC thesis in a few minutes using Do it your way.

A great starting point for your FMC research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If FMC has your attention, do not stop there. Use the Simply Wall St Screener to quickly surface fresh ideas that fit your style before the crowd notices.

• Spot potential bargains early by focusing on companies that our models flag as mispriced. You can start with these 859 undervalued stocks based on cash flows that may warrant a closer look.
• Ride powerful technology shifts by zeroing in on these 29 AI penny stocks that are tied to real business models, not just headlines.
• Target income-focused opportunities by scanning these 11 dividend stocks with yields > 3% that already offer yields above 3% on current prices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.